H. Deng

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

J. Mu, C. Lyu, Yan-yu Jiang, 2021, OncoTargets and therapy.

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease

Xiaofang Wang, Ya-fei Wang, R. Cui, 2021, Frontiers in Immunology.

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma

Z. Qian, J. Mu, Q. Deng, 2021, Cancer science.

Immunochemotherapy as induction treatment in Stage III (N2, N3) Non-small cell lung cancer

W. Liang, J. Li, H. Liang, 2021, medRxiv.

Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti‐CD19‐chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B‐cell lymphoma and high tumor burden

J. Mu, C. Lyu, Jia Wang, 2022, Hematological oncology.

TMEM213 as a novel prognostic and predictive biomarker for patients with lung adenocarcinoma after curative resection: a study based on bioinformatics analysis.

Junli Hao, Mingfang Zhao, H. Deng, 2019, Journal of thoracic disease.